Now showing items 1-12 of 12

    • Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab 

      Sawaya, H.; Sebag, I. A.; Plana, J. C.; Januzzi, James Louis; Ky, B.; Tan, T. C.; Cohen, V.; Banchs, J.; Carver, J. R.; Wiegers, S. E.; Martin, R. P.; Picard, Michael Howard; Gerszten, Robert Edgardo; Halpern, E; Passeri, Jonathan James; Kuter, Irene; Scherrer-Crosbie, Marielle (Ovid Technologies (Wolters Kluwer Health), 2012)
      Background: Because cancer patients survive longer, the impact of cardiotoxicity associated with the use of cancer treatments escalates. The present study investigates whether early alterations of myocardial strain and ...
    • Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation 

      Wong, Eric T; Lok, Edwin; Swanson, Kenneth D (BlackWell Publishing Ltd, 2015)
      The NovoTTF-100A is a device that emits alternating electric fields and it is approved for the treatment of recurrent glioblastoma. It works by perturbing tumor cells during mitosis as they enter anaphase leading to ...
    • Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice 

      Vandenwijngaert, Sara; Swinnen, Melissa; Walravens, Ann-Sophie; Beerens, Manu Eddy Maria; Gillijns, Hilde; Caluwé, Ellen; Tainsh, Robert; Nathan, Daniel I.; Allen, Kaitlin; Brouckaert, Peter; Bartunek, Jozef; Scherrer-Crosbie, Marielle; Bloch, Kenneth; Bloch, Donald Bendit; Janssens, Stefan P.; Buys, Emmanuel (Mary Ann Liebert Inc, 2017)
      Aims: The use of doxorubicin, a potent chemotherapeutic agent, is limited by cardiotoxicity. We tested the hypothesis that decreased soluble guanylate cyclase (sGC) enzyme activity contributes to the development of ...
    • Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003–2008: The Effect of the NCI Clinical Recommendation 

      Bowles, Erin J. Aiello; Wernli, Karen J.; Gray, Heidi J.; Bogart, Andy; Delate, Thomas; O’Keeffe-Rosetti, Maureen; Nekhlyudov, Larissa; Loggers, Elizabeth Trice (Frontiers Media S.A., 2014)
      Purpose: A 2006 National Cancer Institute clinical announcement recommended the use of combined intravenous (IV) and intraperitoneal (IP) chemotherapy over IV chemotherapy alone for women with International Federation of ...
    • Drug Delivery Approaches for the Treatment of Cervical Cancer 

      Ordikhani, Farideh; Erdem Arslan, Mustafa; Marcelo, Raymundo; Sahin, Ilyas; Grigsby, Perry; Schwarz, Julie K.; Azab, Abdel Kareem (MDPI, 2016)
      Cervical cancer is a highly prevalent cancer that affects women around the world. With the availability of new technologies, researchers have increased their efforts to develop new drug delivery systems in cervical cancer ...
    • An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome 

      Galili, Naomi; Tamayo, Pablo; Bosco, Jocelyn; Ladd-Acosta, Christine; Raza, Azra; Ebert, Benjamin L.; Mak, Raymond Heungwing; Pretz, Jennifer Lee; Tanguturi, Shyam Kumar; Stone, Richard Maury; Golub, Todd R. (Public Library of Science, 2008)
      Background: Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition ...
    • Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium 

      Johnatty, S. E.; Tyrer, J. P.; Kar, S.; Beesley, J.; Lu, Y.; Gao, B.; Fasching, P. A.; Hein, A.; Ekici, A. B.; Beckmann, M. W.; Lambrechts, D.; Van Nieuwenhuysen, E.; Vergote, I.; Lambrechts, S.; Rossing, M. A.; Doherty, J. A.; Chang-Claude, J.; Modugno, F.; Ness, R. B.; Moysich, K. B.; Levine, D. A.; Kiemeney, L. A.; Massuger, L. F. A. G.; Gronwald, J.; Lubinski, J.; Jakubowska, A.; Cybulski, C.; Brinton, L.; Lissowska, J.; Wentzensen, N.; Song, H.; Rhenius, V.; Campbell, I.; Eccles, D.; Sieh, W.; Whittemore, A. S.; McGuire, V.; Rothstein, J. H.; Sutphen, R.; Anton-Culver, H.; Ziogas, A.; Gayther, S. A.; Gentry-Maharaj, A.; Menon, U.; Ramus, S. J.; Pearce, C. L.; Pike, M. C.; Stram, D. O.; Wu, A. H.; Kupryjanczyk, J.; Dansonka-Mieszkowska, A.; Rzepecka, I. K.; Spiewankiewicz, B.; Goodman, M. T.; Wilkens, L. R.; Carney, M. E.; Thompson, P. J.; Heitz, F.; du Bois, A.; Schwaab, I.; Harter, P.; Pisterer, J.; Hillemanns, P.; Karlan, B. Y.; Walsh, C.; Lester, J.; Orsulic, S.; Winham, S. J.; Earp, M.; Larson, M. C.; Fogarty, Z. C.; Hogdall, E.; Jensen, A.; Kjaer, S. K.; Fridley, B. L.; Cunningham, J. M.; Vierkant, R. A.; Schildkraut, J. M.; Iversen, E. S.; Terry, Kathryn Lynne; Cramer, Daniel William; Bandera, E. V.; Orlow, I.; Pejovic, T.; Bean, Y.; Hogdall, C.; Lundvall, L.; McNeish, I.; Paul, J.; Carty, K.; Siddiqui, N.; Glasspool, R.; Sellers, T.; Kennedy, C.; Chiew, Y.-E.; Berchuck, A.; MacGregor, S.; Pharoah, P. D. P.; Goode, E. L.; deFazio, A.; Webb, P. M.; Chenevix-Trench, G. (American Association for Cancer Research (AACR), 2015)
      PURPOSE: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. EXPERIMENTAL DESIGN: We analyzed ...
    • Progress in Aptamer-Mediated Drug Delivery Vehicles for Cancer Targeting and Its Implications in Addressing Chemotherapeutic Challenges 

      Zhu, Jie; Huang, He; Dong, Shiwu; Ge, Liang; Zhang, Yuan (Ivyspring International Publisher, 2014)
      Aptamers are novel oligonucleotides with flexible three-dimensional configurations that recognize and bind to their cognate targets, including tumor surface receptors, in a high-affinity and highly specific manner. Because ...
    • The RAS/Mitogen Activated Protein (MAP) Kinase Pathway in Melanoma Biology and Therapeutics 

      Jarell, Abel D; Lawrence, Donald; Tsao, Hensin (Dove Medical Press, 2007)
      An effective treatment for metastatic melanoma remains one of the most elusive goals in all of oncology. Several generations of therapeutic trials have yet to yield any agents that can significantly prolong survival for ...
    • A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer 

      Willett, C. G.; Duda, Dan Gabriel; Ancukiewicz, M; Shah, M.; Czito, B. G.; Bentley, R.; Poleski, M.; Fujita, H.; Lauwers, Gregory Y.; Carroll, M.; Tyler, D.; Mantyh, C.; Shellito, Paul Clarke; Chung, Daniel Chulyong; Clark, Jeffrey William; Jain, Rakesh K. (Alphamed Press, 2010)
      Introduction. Bevacizumab is increasingly being tested with neoadjuvant regimens in patients with localized cancer, but its effects on metastasis and survival remain unknown. This study examines the long-term outcome of ...
    • Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma 

      Stegmaier, Kimberly; Wong, Jenny S; Ross, Kenneth N; Chow, Kwan T; Peck, David; Wright, Renee D; Lessnick, Stephen L; Kung, Andrew Li-Jen; Golub, Todd R. (Public Library of Science, 2007)
      Background: The presence of tumor-specific mutations in the cancer genome represents a potential opportunity for pharmacologic intervention to therapeutic benefit. Unfortunately, many classes of oncoproteins (e.g., ...
    • Vinca alkaloid drugs promote stress-induced translational repression and stress granule formation 

      Szaflarski, Witold; Fay, Marta M.; Kedersha, Nancy; Zabel, Maciej; Anderson, Paul; Ivanov, Pavel (Impact Journals LLC, 2016)
      Resistance to chemotherapy drugs is a serious therapeutic problem and its underlying molecular mechanisms are complex. Stress granules (SGs), cytoplasmic ribonucleoprotein complexes assembled in cells exposed to stress, ...